查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1715756

伴同性动物药物市场：按动物类型、产品类型、分销管道、疾病和配方 - 2025-2030 年全球预测

Companion Animal Pharmaceuticals Market by Animal Type, Product Type, Distribution Channel, Disease Condition, Formulation - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计伴同性动物药物市场规模到 2024 年将达到 175.3 亿美元，到 2025 年将达到 188.5 亿美元，复合年增长率为 7.63%，到 2030 年将达到 272.6 亿美元。

主要市场统计数据
基准年2024年 175.3亿美元
预计2025年 188.5亿美元
预测年份 2030 272.6亿美元
复合年增长率（%） 7.63%

在当今充满活力的伴同性动物医疗保健环境中，药物进步和市场趋势正在以前所未有的速度发展。当前的情况是由突破性的科学创新、加强的监管审查以及对确保世界各地宠物健康的专用药物日益增长的需求所塑造的。这份全面的摘要提供了有关市场发展、基本细分策略和关键策略见解的详细介绍，这将有助于相关人员和决策者专注于新兴的机会和挑战。

说明了广泛的治疗领域和产品线，重点关注伴同性动物药物。了解宏观趋势和细分市场对于产业参与者适应快速变化的市场环境至关重要。该报告提供了以可靠数据和策略远见为依据的深入分析，对于希望推动该行业成长和创新的专业人士来说，是一份重要的指南。

随着对伴同性动物的药品标准和期望不断提高，策略洞察力不仅使公司能够完善产品系列，而且还使它们能够更好地满足全球宠物饲主和兽医专业人士的需求。以下部分深入说明了变革性的市场变化、细緻的细分洞察、区域表现和主要企业分析，这些都是该产业策略规划的支柱。

伴同性动物药物市场的关键变化趋势

伴同性动物药品市场正在经历变革性的变化，这得益于不断的技术进步、不断变化的消费行为以及精准医疗在动物保健中的整合。这些变化加速了新治疗方法的出现，并彻底改变了传统的动物保健方法。近年来，治疗方式明显转向个人化和标靶治疗，这一趋势有望重新定义市场成功之路。

包括基因组研究和数位健康平台的出现在内的技术创新现在在产品开发和客户参与中发挥核心作用。这种转变不仅是对当前市场需求的回应，也是面向未来投资的主动飞跃。越来越多的公司开始转向数位转型，以简化研究、开发和分销流程，并提高产品的功效和安全性。

市场参与企业也在重新思考如何配製、测试和交付他们的产品。生技药品开发，特别是干扰素和疫苗领域的开发，正在突破传统药物开发的界限。新型抗菌和促生长药用饲料添加剂的开发也呈现出显着势头，推动着从传统策略转向更具创新性和科学性的解决方案的模式转移。

这些转变正在对整个产业产生连锁反应，影响从法律规范到消费者态度的各个层面。相关人员现在正在探索一个以数据主导决策和以客户为中心的策略为基础的环境。更强大的市场分析和技术整合将使公司能够快速转变以抓住新的商机，同时保持高合规标准。因此，市场正在经历强劲成长，重点关注前沿研究、扩大分销管道和推动永续市场发展的策略伙伴关係。

关键细分洞察

市场区隔分析揭示了定义伴同性动物药物的复杂层面。从动物种类来看，市场涵盖了鸟类、猫、狗和马等多种物种。例如，进一步分析猫类别，了解抗生素、抗真菌药物和疫苗，以反映有针对性的治疗需求。同样，对狗的评估涵盖抗生素、跳蚤和蜱虫药物、止痛药和疫苗等多个方面，从而全面了解这群人所面临的健康挑战。同时，在马科动物领域，已经推出了以驱虫剂、关节保健产品、生殖疗法和疫苗为重点的产品系列，为高性能动物提供所需的专业关注。

从产品类型来看，细分策略深入生物製药、药用饲料添加剂和药品。干扰素和疫苗等生物製药凸显了向更复杂、更有效的医疗介入的转变。药用饲料添加剂分为抗菌剂和生长促进剂，强调动物营养和治疗之间的微妙平衡。此外，药品分为非处方药和处方药，以全面了解不同产品组的可用性和监管监督。

市场还根据分销管道进行分析，线上零售商、连锁药局和兽医诊所对于最终用户如何获得产品起着至关重要的作用。这些见解揭示了消费行为变化的趋势，数位平台日益成为传统供应链中强大的竞争对手。

疾病状况细分更为清晰，以慢性病、肠胃疾病、感染疾病为主要调查领域。在消化器官系统病和感染疾病领域，我们详细研究了结肠炎、发炎性肠道疾病肠道疾病、细菌和病毒感染疾病等子区隔，以说明市场的多层次复杂性。最后，配方细分凸显了产品传输机制的重要性，注射剂、溶液和锭剂概述了治疗的给药方式，每种製剂都有其独特的研发重点。

这些细分见解与全面了解市场需求和消费者行为的通用目标交织在一起。这种复杂的映射可帮助行业专业人士识别机会、客製化行销策略并使产品开发与不同动物群和治疗类别的不同需求保持一致。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 宠物拥有增加和宠物人性化
      • 可支配收入的增加推动了先进兽医和医药护理的支出
      • 改善线上兽医保健平台的可近性将促进药品销售
    • 限制因素
      • 农村基础设施的限制限制了伴同性动物药物的取得
    • 机会
      • 利用先进的兽医远端医疗服务扩大您的医药市场范围
      • 旨在缓解老年犬关节炎的药物创新
    • 任务
      • 克服监管障碍并确保动物用药品的合规性
  • 市场区隔分析
    • 产品类型：由于成药供应充足，人们对非处方药的兴趣日益浓厚
    • 分销通路：线上零售通路因其可访问性和便利性而日益成为首选通路
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社会
    • 技术的
    • 合法的
    • 环境

第六章伴同性动物药物市场（依动物类型）

  • 鸟
  • 猫
    • 抗生素
    • 抗真菌药物
    • 疫苗
  • 狗
    • 抗生素
    • 跳蚤和蜱虫控制
    • 止痛药
    • 疫苗
  • 马
    • 驱虫药
    • 关节保健产品
    • 生殖治疗
    • 疫苗

第七章伴同性动物药物市场（依产品类型）

  • 生物製药
    • 干扰素
    • 疫苗
  • 药品和饲料添加剂
    • 抗菌剂
    • 生长促进剂
  • 製药
    • 非处方药
    • 处方药

第 8 章伴同性动物药物市场（依通路）

  • 线上零售商
  • 药局连锁
  • 兽医诊所

第九章伴同性动物药物市场（依疾病状况）

  • 慢性病
  • 胃肠道问题
    • 结肠炎
    • 发炎性肠道疾病
  • 感染疾病
    • 细菌感染疾病
    • 病毒感染

第 10 章伴同性动物药物市场（以剂型）

  • 注射
  • 液体
  • 药片

11.美洲伴同性动物药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

12. 亚太地区伴同性动物药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

13. 欧洲、中东和非洲伴同性动物药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十四章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争情境分析
  • 战略分析与建议

公司名单

  • Alivira Animal Health Limited
  • Ashish Life Science Pvt. Ltd.
  • Boehringer Ingelheim International GmbH
  • Century Pharmaceuticals Ltd.
  • Ceva Sante Animale
  • Chanelle Pharma
  • Dechra Pharmaceuticals PLC
  • Eco Animal Health Group PLC
  • Elanco Animal Health Incorporated
  • Endovac Animal Health, LLC
  • Hester Biosciences Limited
  • Hipra Laboratories, SA
  • Indian Immunologicals Ltd.
  • Kyoritsu Seiyaku Corporation
  • Lutim Pharma Pvt. Ltd.
  • Meiji Group
  • Merck & Co. Inc.
  • Neogen Corporation
  • Norbrook Laboratories Ltd.
  • Orion Corporation
  • Phibro Animal Health Corporation
  • SkyEc Pharmaceuticals Private Limited
  • Stanex Drugs and Chemicals Pvt Ltd.
  • Tianjin Ringpu Biotechnology Co., Ltd.
  • Veko Care
  • Vetbiolix
  • Vetneeds Group
  • Virbac SA
  • Zoetis Inc.
  • Zydus Animal Health
Product Code: MRR-FD3F12D52B58

The Companion Animal Pharmaceuticals Market was valued at USD 17.53 billion in 2024 and is projected to grow to USD 18.85 billion in 2025, with a CAGR of 7.63%, reaching USD 27.26 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 17.53 billion
Estimated Year [2025] USD 18.85 billion
Forecast Year [2030] USD 27.26 billion
CAGR (%) 7.63%

In today's dynamic healthcare environment for companion animals, pharmaceutical advancements and market trends are evolving at an unprecedented pace. The current climate is shaped by groundbreaking scientific innovations, increased regulatory scrutiny, and a rising demand for specialized medications that ensure the well-being of pets worldwide. This comprehensive summary offers an in-depth view of the market's evolution, fundamental segmentation strategies, and key strategic insights that will help stakeholders and decision-makers hone in on emerging opportunities and challenges.

With a focus on companion animal pharmaceuticals, the narrative spans an expansive spectrum of therapeutic areas and product lines. As industry players adapt to the rapidly changing landscape, understanding both macroscopic trends and granular market segments is essential. This report provides thorough analysis backed by robust data and strategic foresight, making it an indispensable guide for professionals seeking to harness growth and drive innovation in the sector.

As the pharmaceutical standards and expectations for companion animals continue to rise, strategic insights not only enable organizations to refine their product portfolios but also to better cater to the needs of pet owners and veterinary professionals globally. The following sections present a detailed exploration of transformative market shifts, nuanced segmentation insights, regional performance, and key company analyses that form the backbone of strategic planning in the industry.

Key Transformative Shifts in the Companion Animal Pharmaceuticals Landscape

The companion animal pharmaceuticals market is undergoing transformative shifts spurred by continuous technological advances, evolving consumer behavior, and the integration of precision medicine in veterinary care. These changes have accelerated the emergence of new treatment modalities and revolutionized traditional approaches to animal health. Over the past few years, there has been a marked shift towards more personalized and targeted therapies, and this trend is poised to redefine the pathways to market success.

Technological innovation, including the advent of genomic studies and digital health platforms, now plays a central role in product development and customer engagement. This shift is not just a response to current market demands but a proactive leap towards future-proofing investments. Companies are increasingly focusing on digital transformation to streamline their research, development, and distribution processes, which in turn enhances product efficacy and safety.

Market participants are also rethinking how products are formulated, tested, and delivered. Advances in biologics, particularly in the realm of interferons and vaccines, are pushing the boundaries of traditional drug development. There is also significant momentum behind developing medicated feed additives with novel antimicrobial and growth-promoting properties, further underscoring a paradigm shift from conventional strategies to more innovative, scientifically robust solutions.

These shifts have had ripple effects across the industry, impacting everything from regulatory frameworks to consumer awareness. Stakeholders now navigate a landscape where data-driven decision making and customer-centric strategies are fundamental. With more robust market analytics and technology integration, companies can pivot faster to seize emerging opportunities while maintaining high compliance standards. Consequently, the market is experiencing robust growth, realigning its focus towards cutting-edge research, expanded distribution channels, and strategic partnerships that collectively drive sustainable market evolution.

Key Segmentation Insights

Analysis of market segmentation reveals intricate layers that define the companion animal pharmaceuticals landscape. When studied from the perspective of animal type, the market encompasses a wide range of species such as birds, cats, dogs, and horses. The category of cats, for instance, is analyzed further with insights into antibiotics, antifungal medications, and vaccines, reflecting targeted therapeutic needs. Similarly, dogs are evaluated through segments including antibiotics, flea and tick treatments, pain relief medications, and vaccines, highlighting the broad spectrum of health challenges faced by this group. Meanwhile, the equine segment unveils a range of products focusing on dewormers, joint health products, reproductive therapies, and vaccines, pinpointing the specialty focus necessary for these high-performance animals.

Looking from a product type perspective, the segmentation strategy delves into biologics, medicated feed additives, and pharmaceutical drugs. Biological products, including interferons and vaccines, underscore the shift toward more sophisticated and efficacious medical interventions. Medicated feed additives are dissected into antimicrobials and growth promoters, emphasizing the nuanced balance between animal nutrition and therapeutic care. Further, pharmaceutical drugs are divided into over-the-counter and prescription drugs, capturing a comprehensive picture of accessibility and regulatory oversight across varied product offerings.

The market is also dissected based on distribution channels where online retailers, pharmacy chains, and veterinary clinics play a significant role in how products are accessed by end users. Such insights reveal trends in shifting consumer behavior, with digital platforms increasingly emerging as strong contenders in the traditional supply chain narrative.

Disease condition segmentation provides further clarity, with chronic conditions, gastrointestinal issues, and infectious diseases forming the primary categories of investigation. Within gastrointestinal and infectious diseases, sub-segments such as colitis, inflammatory bowel disease, as well as bacterial and viral infections are examined in detail, showcasing the market's layered complexity. Finally, the formulation segmentation underscores the importance of product delivery mechanisms, where injectables, liquids, and tablets outline the methods through which therapies are administered, each with their own research and development priorities.

Together, these segmentation insights are interwoven by a common objective: to provide an all-encompassing understanding of market demands and consumer behavior. This intricate mapping helps industry professionals pinpoint opportunities, tailor marketing strategies, and align product development with the diverse needs of different animal segments and therapeutic categories.

Based on Animal Type, market is studied across Birds, Cats, Dogs, and Horses. The Cats is further studied across Antibiotics, Antifungal Medications, and Vaccines. The Dogs is further studied across Antibiotics, Flea & Tick Treatments, Pain Relief Medications, and Vaccines. The Horses is further studied across Dewormers, Joint Health Products, Reproductive Therapies, and Vaccines.

Based on Product Type, market is studied across Biologics, Medicated Feed Additives, and Pharmaceutical Drugs. The Biologics is further studied across Interferons and Vaccines. The Medicated Feed Additives is further studied across Antimicrobials and Growth Promoters. The Pharmaceutical Drugs is further studied across Over-The-Counter Drugs and Prescription Drugs.

Based on Distribution Channel, market is studied across Online Retailers, Pharmacy Chains, and Veterinary Clinics.

Based on Disease Condition, market is studied across Chronic Conditions, Gastrointestinal Issues, and Infectious Diseases. The Gastrointestinal Issues is further studied across Colitis and Inflammatory Bowel Disease. The Infectious Diseases is further studied across Bacterial Infections and Viral Infections.

Based on Formulation, market is studied across Injectables, Liquids, and Tablets.

Regional Insights in the Global Companion Animal Pharmaceuticals Market

The global footprint of the companion animal pharmaceuticals market divides itself into distinct geographical regions, each offering unique insights and growth trajectories that underline the industry's multifaceted nature. In the Americas, market dynamics are shaped by robust research infrastructure and high consumer spending power, fueling a competitive environment where advanced therapeutics rapidly gain traction. Here, highly developed veterinary healthcare systems and a growing consciousness regarding pet well-being contribute to the rising adoption of innovative pharmaceuticals and therapies.

The region comprising Europe, the Middle East, and Africa presents a landscape characterized by regulatory rigor and evolving market norms. Progressive veterinary care in Europe combined with emerging healthcare frameworks in the Middle East and Africa creates a diverse backdrop for market players, offering both challenges and opportunities. Companies need to tailor their strategies to navigate varying regulatory environments while addressing the distinct therapeutic demands of each sub-region.

The Asia-Pacific region stands out with its accelerating market growth powered by expanding urbanization, increasing pet ownership, and rising disposable incomes. Rapid modernization in veterinary practices, coupled with significant investments in research and local manufacturing capabilities, is propelling the companion animal pharmaceuticals market forward in this region. Trends in consumer behavior and a burgeoning middle class have also contributed to a noticeable shift in demand profiles, making Asia-Pacific a critical region for both established and emerging players.

These regional insights emphasize the importance of geographical tailor-made strategies in addressing both market-specific challenges and opportunities. By understanding regional consumer trends, competitive dynamics, and evolving regulatory landscapes, stakeholders can better navigate the intricacies of international market expansion and competitive positioning.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Company Insights: Key Player Analysis in the Companion Animal Pharmaceuticals Field

The competitive landscape within the companion animal pharmaceuticals market is defined by several key companies, each bringing unique strengths, innovative capabilities, and strategic market approaches. A diverse set of industry leaders, including Alivira Animal Health Limited and Ashish Life Science Pvt. Ltd., continue to push the boundaries of what is possible in veterinary pharmaceuticals. With historical strength and continuous R&D investments, companies like Boehringer Ingelheim International GmbH and Century Pharmaceuticals Ltd. have established themselves as pivotal players in the domain.

Global giants such as Ceva Sante Animale, coupled with the innovative contributions from Chanelle Pharma and Dechra Pharmaceuticals PLC, highlight a marketplace that thrives on both legacy and innovation. Organizations like Eco Animal Health Group PLC and Elanco Animal Health Incorporated have successfully integrated market insights with a forward-looking product pipeline, ensuring that their advances align closely with consumer needs and regulatory demands. Similarly, companies including Endovac Animal Health, LLC and Hester Biosciences Limited have marked their territory through specialized product offerings and comprehensive research initiatives.

Notably, industry forerunners such as Hipra Laboratories, S.A. and Indian Immunologicals Ltd. have played instrumental roles in driving scientific innovation and expanding access to next-generation therapies. Strategic expansions and global market penetration efforts by Kyoritsu Seiyaku Corporation, Lutim Pharma Pvt. Ltd., and the Meiji Group further consolidate the competitive dynamics within the market. Meanwhile, leading firms like Merck & Co. Inc. and Neogen Corporation continue to fortify their positions by embracing technological integration and robust distribution strategies.

Equally competitive are specialized entities like Norbrook Laboratories Ltd. and Orion Corporation, which have carved out niche segments within the broader industry landscape. Phibro Animal Health Corporation and SkyEc Pharmaceuticals Private Limited distinguish themselves through focused product portfolios and innovative market strategies that directly address the evolving needs of veterinary care. Companies such as Stanex Drugs and Chemicals Pvt Ltd., Tianjin Ringpu Biotechnology Co., Ltd., and Veko Care showcase the dynamic interplay between traditional expertise and emerging technologies across the market. In addition, Vetbiolix, Vetneeds Group, and Virbac S.A. add to the robust competitive fabric of the industry, while globally recognized brands such as Zoetis Inc. and Zydus Animal Health further underscore the influence of comprehensive research, rigorous quality control, and strategic marketing initiatives.

This analysis of key companies reveals a market that is both competitive and collaborative, characterized by a shared commitment to innovation and the continuous delivery of high-quality pharmaceutical solutions. Stakeholders not only benefit from the wealth of expertise that these organizations represent but also from the diverse strategic approaches that drive the evolution of the companion animal pharmaceuticals market.

The report delves into recent significant developments in the Companion Animal Pharmaceuticals Market, highlighting leading vendors and their innovative profiles. These include Alivira Animal Health Limited, Ashish Life Science Pvt. Ltd., Boehringer Ingelheim International GmbH, Century Pharmaceuticals Ltd., Ceva Sante Animale, Chanelle Pharma, Dechra Pharmaceuticals PLC, Eco Animal Health Group PLC, Elanco Animal Health Incorporated, Endovac Animal Health, LLC, Hester Biosciences Limited, Hipra Laboratories, S.A., Indian Immunologicals Ltd., Kyoritsu Seiyaku Corporation, Lutim Pharma Pvt. Ltd., Meiji Group, Merck & Co. Inc., Neogen Corporation, Norbrook Laboratories Ltd., Orion Corporation, Phibro Animal Health Corporation, SkyEc Pharmaceuticals Private Limited, Stanex Drugs and Chemicals Pvt Ltd., Tianjin Ringpu Biotechnology Co., Ltd., Veko Care, Vetbiolix, Vetneeds Group, Virbac S.A., Zoetis Inc., and Zydus Animal Health. Actionable Recommendations for Leaders in the Companion Animal Pharmaceuticals Sector

Industry leaders must adopt a multifaceted strategy to stay ahead in the ever-changing companion animal pharmaceuticals space. The first recommendation is to invest robustly in R&D initiatives that leverage cutting-edge technology and scientific discoveries. Firms should prioritize collaborations with research institutions and technological partners to accelerate the development process for new vaccines, biologics, and innovative pharmaceutical formulations. Aligning research efforts with emerging global health trends and regulatory updates also ensures that products remain both relevant and compliant.

A second strategic emphasis is the need to diversify product portfolios and optimize distribution channels. With evolving consumer behaviors leading to an increased reliance on online retail platforms and specialized veterinary clinics, companies should re-examine their marketing and distribution strategies to enhance product accessibility and customer engagement. Embracing digital transformation and data analytics will facilitate more effective supply chain management and enable targeted marketing strategies that resonate with a global customer base.

Leaders should also focus on market segmentation by closely monitoring the therapeutic requirements of different companion animal groups. By deeply understanding the intricate differences among segments such as the varied needs of cats, dogs, horses, and birds, organizations can tailor product development and marketing communications to address specific gaps in the market. Additionally, considering aspects such as formulation preferences and treatment modalities will provide a competitive edge.

Finally, fostering strategic partnerships and establishing long-term collaborations can drive operational efficiencies and bolster market penetration. Cross-functional alliances with stakeholders across the value chain-from manufacturers and suppliers to veterinary service providers-can streamline operations and offer integrated solutions that span from diagnosis to treatment. By integrating these actionable insights, leaders in the sector can not only enhance operational fluidity but also strategically position their organizations to capture emerging market opportunities.

Executive Conclusion for Strategic Industry Decision-Making

In summary, the companion animal pharmaceuticals market is a vibrant and fast-evolving landscape where innovation meets opportunity. The insights presented here underscore the critical importance of embracing transformative trends, comprehensive segmentation, and region-specific strategies that together pave the path for future growth. The detailed examination of animal types, product streams, and distribution channels, combined with a nuanced understanding of disease conditions and formulation methods, provides a holistic view of the industry's complexities.

This analysis reiterates that sector growth is fueled by investments in research and digital innovation, as well as by strategic partnerships and diversified product portfolios. Regional trends from the Americas to Asia-Pacific, alongside the competitive dynamism of key companies, paint a picture of an industry that is not only adaptive but also forward-thinking. Stakeholders who harness these insights can design strategies that are both resilient and flexible in the face of changing market dynamics.

In closing, the integration of scientific research, technological advancement, and comprehensive market understanding is essential for sustained growth and competitive advantage. The sector's evolution is marked by continuous learning and adaptation, making it imperative for companies and decision-makers to remain agile, data-driven, and customer-centric. These refined approaches are expected to pave the way for sustained growth and innovation across the companion animal pharmaceuticals market.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing pet ownership and humanization of pets
      • 5.1.1.2. Rising disposable incomes enabling higher expenditure on advanced veterinary and pharmaceutical care
      • 5.1.1.3. Improved access to online veterinary healthcare platforms driving pharmaceutical sales
    • 5.1.2. Restraints
      • 5.1.2.1. Infrastructure constraints in rural areas limiting access to companion animal pharmaceuticals
    • 5.1.3. Opportunities
      • 5.1.3.1. Leveraging advanced veterinary telehealth services to expand pharmaceutical market reach
      • 5.1.3.2. Innovations in medications designed for canine arthritis relief in senior dogs
    • 5.1.4. Challenges
      • 5.1.4.1. Navigating regulatory hurdles and ensuring compliance in animal pharmaceuticals
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product Type: Growing preference for OTC drugs owing to easy accessibility
    • 5.2.2. Distribution Channel: Increased preference for online retailers channel owing to accessibility and convenience
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Companion Animal Pharmaceuticals Market, by Animal Type

  • 6.1. Introduction
  • 6.2. Birds
  • 6.3. Cats
    • 6.3.1. Antibiotics
    • 6.3.2. Antifungal Medications
    • 6.3.3. Vaccines
  • 6.4. Dogs
    • 6.4.1. Antibiotics
    • 6.4.2. Flea & Tick Treatments
    • 6.4.3. Pain Relief Medications
    • 6.4.4. Vaccines
  • 6.5. Horses
    • 6.5.1. Dewormers
    • 6.5.2. Joint Health Products
    • 6.5.3. Reproductive Therapies
    • 6.5.4. Vaccines

7. Companion Animal Pharmaceuticals Market, by Product Type

  • 7.1. Introduction
  • 7.2. Biologics
    • 7.2.1. Interferons
    • 7.2.2. Vaccines
  • 7.3. Medicated Feed Additives
    • 7.3.1. Antimicrobials
    • 7.3.2. Growth Promoters
  • 7.4. Pharmaceutical Drugs
    • 7.4.1. Over-The-Counter Drugs
    • 7.4.2. Prescription Drugs

8. Companion Animal Pharmaceuticals Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Online Retailers
  • 8.3. Pharmacy Chains
  • 8.4. Veterinary Clinics

9. Companion Animal Pharmaceuticals Market, by Disease Condition

  • 9.1. Introduction
  • 9.2. Chronic Conditions
  • 9.3. Gastrointestinal Issues
    • 9.3.1. Colitis
    • 9.3.2. Inflammatory Bowel Disease
  • 9.4. Infectious Diseases
    • 9.4.1. Bacterial Infections
    • 9.4.2. Viral Infections

10. Companion Animal Pharmaceuticals Market, by Formulation

  • 10.1. Introduction
  • 10.2. Injectables
  • 10.3. Liquids
  • 10.4. Tablets

11. Americas Companion Animal Pharmaceuticals Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Companion Animal Pharmaceuticals Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Companion Animal Pharmaceuticals Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Boehringer Ingelheim enhances companion animal pharmaceuticals through acquisition of Saiba Animal Health
    • 14.3.2. Boehringer Ingelheim introduces NexGard SPECTRA in India, a new chewable solution for comprehensive dog parasite protection
    • 14.3.3. ENTOD Pharmaceuticals launches FUR by ENTOD, pioneering eye and ear care solutions for pets worldwide
    • 14.3.4. Zoetis Receives FDA Approval for Groundbreaking Canine Osteoarthritis and Allergy Treatments
    • 14.3.5. Akston Biosciences Shifts Focus to Pet Health, Using Cutting-Edge Technology to Develop New Treatments
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Alivira Animal Health Limited
  • 2. Ashish Life Science Pvt. Ltd.
  • 3. Boehringer Ingelheim International GmbH
  • 4. Century Pharmaceuticals Ltd.
  • 5. Ceva Sante Animale
  • 6. Chanelle Pharma
  • 7. Dechra Pharmaceuticals PLC
  • 8. Eco Animal Health Group PLC
  • 9. Elanco Animal Health Incorporated
  • 10. Endovac Animal Health, LLC
  • 11. Hester Biosciences Limited
  • 12. Hipra Laboratories, S.A.
  • 13. Indian Immunologicals Ltd.
  • 14. Kyoritsu Seiyaku Corporation
  • 15. Lutim Pharma Pvt. Ltd.
  • 16. Meiji Group
  • 17. Merck & Co. Inc.
  • 18. Neogen Corporation
  • 19. Norbrook Laboratories Ltd.
  • 20. Orion Corporation
  • 21. Phibro Animal Health Corporation
  • 22. SkyEc Pharmaceuticals Private Limited
  • 23. Stanex Drugs and Chemicals Pvt Ltd.
  • 24. Tianjin Ringpu Biotechnology Co., Ltd.
  • 25. Veko Care
  • 26. Vetbiolix
  • 27. Vetneeds Group
  • 28. Virbac S.A.
  • 29. Zoetis Inc.
  • 30. Zydus Animal Health

LIST OF FIGURES

  • FIGURE 1. COMPANION ANIMAL PHARMACEUTICALS MARKET MULTI-CURRENCY
  • FIGURE 2. COMPANION ANIMAL PHARMACEUTICALS MARKET MULTI-LANGUAGE
  • FIGURE 3. COMPANION ANIMAL PHARMACEUTICALS MARKET RESEARCH PROCESS
  • FIGURE 4. COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2024 VS 2030 (%)
  • FIGURE 17. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 19. AMERICAS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 21. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. COMPANION ANIMAL PHARMACEUTICALS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 27. COMPANION ANIMAL PHARMACEUTICALS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. COMPANION ANIMAL PHARMACEUTICALS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. COMPANION ANIMAL PHARMACEUTICALS MARKET DYNAMICS
  • TABLE 7. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIRDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY CATS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIFUNGAL MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY CATS, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DOGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FLEA & TICK TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PAIN RELIEF MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DOGS, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY HORSES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DEWORMERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY JOINT HEALTH PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY REPRODUCTIVE THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY HORSES, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INTERFERONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY MEDICATED FEED ADDITIVES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIMICROBIALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GROWTH PROMOTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY MEDICATED FEED ADDITIVES, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PHARMACEUTICAL DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRESCRIPTION DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PHARMACEUTICAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ONLINE RETAILERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PHARMACY CHAINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY CHRONIC CONDITIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY COLITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 54. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INJECTABLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 55. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIQUIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 56. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY CATS, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DOGS, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY HORSES, 2018-2030 (USD MILLION)
  • TABLE 61. AMERICAS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. AMERICAS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 63. AMERICAS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY MEDICATED FEED ADDITIVES, 2018-2030 (USD MILLION)
  • TABLE 64. AMERICAS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PHARMACEUTICAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 65. AMERICAS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. AMERICAS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 67. AMERICAS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2018-2030 (USD MILLION)
  • TABLE 68. AMERICAS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 69. AMERICAS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 70. AMERICAS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 71. ARGENTINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. ARGENTINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY CATS, 2018-2030 (USD MILLION)
  • TABLE 73. ARGENTINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DOGS, 2018-2030 (USD MILLION)
  • TABLE 74. ARGENTINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY HORSES, 2018-2030 (USD MILLION)
  • TABLE 75. ARGENTINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. ARGENTINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 77. ARGENTINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY MEDICATED FEED ADDITIVES, 2018-2030 (USD MILLION)
  • TABLE 78. ARGENTINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PHARMACEUTICAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 79. ARGENTINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. ARGENTINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 81. ARGENTINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2018-2030 (USD MILLION)
  • TABLE 82. ARGENTINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 83. ARGENTINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 84. BRAZIL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. BRAZIL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY CATS, 2018-2030 (USD MILLION)
  • TABLE 86. BRAZIL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DOGS, 2018-2030 (USD MILLION)
  • TABLE 87. BRAZIL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY HORSES, 2018-2030 (USD MILLION)
  • TABLE 88. BRAZIL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. BRAZIL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 90. BRAZIL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY MEDICATED FEED ADDITIVES, 2018-2030 (USD MILLION)
  • TABLE 91. BRAZIL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PHARMACEUTICAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 92. BRAZIL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. BRAZIL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 94. BRAZIL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2018-2030 (USD MILLION)
  • TABLE 95. BRAZIL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 96. BRAZIL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 97. CANADA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. CANADA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY CATS, 2018-2030 (USD MILLION)
  • TABLE 99. CANADA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DOGS, 2018-2030 (USD MILLION)
  • TABLE 100. CANADA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY HORSES, 2018-2030 (USD MILLION)
  • TABLE 101. CANADA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. CANADA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 103. CANADA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY MEDICATED FEED ADDITIVES, 2018-2030 (USD MILLION)
  • TABLE 104. CANADA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PHARMACEUTICAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 105. CANADA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 106. CANADA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 107. CANADA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2018-2030 (USD MILLION)
  • TABLE 108. CANADA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 109. CANADA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 110. MEXICO COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. MEXICO COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY CATS, 2018-2030 (USD MILLION)
  • TABLE 112. MEXICO COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DOGS, 2018-2030 (USD MILLION)
  • TABLE 113. MEXICO COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY HORSES, 2018-2030 (USD MILLION)
  • TABLE 114. MEXICO COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. MEXICO COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 116. MEXICO COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY MEDICATED FEED ADDITIVES, 2018-2030 (USD MILLION)
  • TABLE 117. MEXICO COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PHARMACEUTICAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 118. MEXICO COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 119. MEXICO COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 120. MEXICO COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2018-2030 (USD MILLION)
  • TABLE 121. MEXICO COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 122. MEXICO COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 123. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY CATS, 2018-2030 (USD MILLION)
  • TABLE 125. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DOGS, 2018-2030 (USD MILLION)
  • TABLE 126. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY HORSES, 2018-2030 (USD MILLION)
  • TABLE 127. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 129. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY MEDICATED FEED ADDITIVES, 2018-2030 (USD MILLION)
  • TABLE 130. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PHARMACEUTICAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 131. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 132. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 133. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2018-2030 (USD MILLION)
  • TABLE 134. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 135. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 136. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY CATS, 2018-2030 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DOGS, 2018-2030 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY HORSES, 2018-2030 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY MEDICATED FEED ADDITIVES, 2018-2030 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PHARMACEUTICAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2018-2030 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 151. AUSTRALIA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. AUSTRALIA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY CATS, 2018-2030 (USD MILLION)
  • TABLE 153. AUSTRALIA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DOGS, 2018-2030 (USD MILLION)
  • TABLE 154. AUSTRALIA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY HORSES, 2018-2030 (USD MILLION)
  • TABLE 155. AUSTRALIA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. AUSTRALIA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 157. AUSTRALIA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY MEDICATED FEED ADDITIVES, 2018-2030 (USD MILLION)
  • TABLE 158. AUSTRALIA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PHARMACEUTICAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 159. AUSTRALIA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 160. AUSTRALIA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 161. AUSTRALIA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2018-2030 (USD MILLION)
  • TABLE 162. AUSTRALIA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 163. AUSTRALIA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 164. CHINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. CHINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY CATS, 2018-2030 (USD MILLION)
  • TABLE 166. CHINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DOGS, 2018-2030 (USD MILLION)
  • TABLE 167. CHINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY HORSES, 2018-2030 (USD MILLION)
  • TABLE 168. CHINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. CHINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 170. CHINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY MEDICATED FEED ADDITIVES, 2018-2030 (USD MILLION)
  • TABLE 171. CHINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PHARMACEUTICAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 172. CHINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 173. CHINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 174. CHINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2018-2030 (USD MILLION)
  • TABLE 175. CHINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 176. CHINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 177. INDIA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. INDIA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY CATS, 2018-2030 (USD MILLION)
  • TABLE 179. INDIA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DOGS, 2018-2030 (USD MILLION)
  • TABLE 180. INDIA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY HORSES, 2018-2030 (USD MILLION)
  • TABLE 181. INDIA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. INDIA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 183. INDIA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY MEDICATED FEED ADDITIVES, 2018-2030 (USD MILLION)
  • TABLE 184. INDIA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PHARMACEUTICAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 185. INDIA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 186. INDIA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 187. INDIA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2018-2030 (USD MILLION)
  • TABLE 188. INDIA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 189. INDIA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 190. INDONESIA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. INDONESIA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY CATS, 2018-2030 (USD MILLION)
  • TABLE 192. INDONESIA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DOGS, 2018-2030 (USD MILLION)
  • TABLE 193. INDONESIA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY HORSES, 2018-2030 (USD MILLION)
  • TABLE 194. INDONESIA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. INDONESIA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 196. INDONESIA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY MEDICATED FEED ADDITIVES, 2018-2030 (USD MILLION)
  • TABLE 197. INDONESIA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PHARMACEUTICAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 198. INDONESIA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 199. INDONESIA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 200. INDONESIA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2018-2030 (USD MILLION)
  • TABLE 201. INDONESIA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 202. INDONESIA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 203. JAPAN COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. JAPAN COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY CATS, 2018-2030 (USD MILLION)
  • TABLE 205. JAPAN COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DOGS, 2018-2030 (USD MILLION)
  • TABLE 206. JAPAN COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY HORSES, 2018-2030 (USD MILLION)
  • TABLE 207. JAPAN COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. JAPAN COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 209. JAPAN COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY MEDICATED FEED ADDITIVES, 2018-2030 (USD MILLION)
  • TABLE 210. JAPAN COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PHARMACEUTICAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 211. JAPAN COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 212. JAPAN COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 213. JAPAN COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2018-2030 (USD MILLION)
  • TABLE 214. JAPAN COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 215. JAPAN COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 216. MALAYSIA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. MALAYSIA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY CATS, 2018-2030 (USD MILLION)
  • TABLE 218. MALAYSIA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DOGS, 2018-2030 (USD MILLION)
  • TABLE 219. MALAYSIA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY HORSES, 2018-2030 (USD MILLION)
  • TABLE 220. MALAYSIA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. MALAYSIA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 222. MALAYSIA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY MEDICATED FEED ADDITIVES, 2018-2030 (USD MILLION)
  • TABLE 223. MALAYSIA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PHARMACEUTICAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 224. MALAYSIA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 225. MALAYSIA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 226. MALAYSIA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2018-2030 (USD MILLION)
  • TABLE 227. MALAYSIA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 228. MALAYSIA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 229. PHILIPPINES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 230. PHILIPPINES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY CATS, 2018-2030 (USD MILLION)
  • TABLE 231. PHILIPPINES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DOGS, 2018-2030 (USD MILLION)
  • TABLE 232. PHILIPPINES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY HORSES, 2018-2030 (USD MILLION)
  • TABLE 233. PHILIPPINES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. PHILIPPINES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 235. PHILIPPINES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY MEDICATED FEED ADDITIVES, 2018-2030 (USD MILLION)
  • TABLE 236. PHILIPPINES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PHARMACEUTICAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 237. PHILIPPINES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 238. PHILIPPINES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 239. PHILIPPINES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2018-2030 (USD MILLION)
  • TABLE 240. PHILIPPINES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 241. PHILIPPINES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 242. SINGAPORE COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 243. SINGAPORE COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY CATS, 2018-2030 (USD MILLION)
  • TABLE 244. SINGAPORE COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DOGS, 2018-2030 (USD MILLION)
  • TABLE 245. SINGAPORE COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY HORSES, 2018-2030 (USD MILLION)
  • TABLE 246. SINGAPORE COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 247. SINGAPORE COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 248. SINGAPORE COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY MEDICATED FEED ADDITIVES, 2018-2030 (USD MILLION)
  • TABLE 249. SINGAPORE COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PHARMACEUTICAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 250. SINGAPORE COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 251. SINGAPORE COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 252. SINGAPORE COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2018-2030 (USD MILLION)
  • TABLE 253. SINGAPORE COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 254. SINGAPORE COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 255. SOUTH KOREA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 256. SOUTH KOREA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY CATS, 2018-2030 (USD MILLION)
  • TABLE 257. SOUTH KOREA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DOGS, 2018-2030 (USD MILLION)
  • TABLE 258. SOUTH KOREA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY HORSES, 2018-2030 (USD MILLION)
  • TABLE 259. SOUTH KOREA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 260. SOUTH KOREA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 261. SOUTH KOREA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY MEDICATED FEED ADDITIVES, 2018-2030 (USD MILLION)
  • TABLE 262. SOUTH KOREA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PHARMACEUTICAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 263. SOUTH KOREA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 264. SOUTH KOREA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 265. SOUTH KOREA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2018-2030 (USD MILLION)
  • TABLE 266. SOUTH KOREA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 267. SOUTH KOREA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 268. TAIWAN COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 269. TAIWAN COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY CATS, 2018-2030 (USD MILLION)
  • TABLE 270. TAIWAN COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DOGS, 2018-2030 (USD MILLION)
  • TABLE 271. TAIWAN COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY HORSES, 2018-2030 (USD MILLION)
  • TABLE 272. TAIWAN COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 273. TAIWAN COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 274. TAIWAN COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY MEDICATED FEED ADDITIVES, 2018-2030 (USD MILLION)
  • TABLE 275. TAIWAN COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PHARMACEUTICAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 276. TAIWAN COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 277. TAIWAN COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 278. TAIWAN COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2018-2030 (USD MILLION)
  • TABLE 279. TAIWAN COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 280. TAIWAN COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 281. THAILAND COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 282. THAILAND COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY CATS, 2018-2030 (USD MILLION)
  • TABLE 283. THAILAND COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DOGS, 2018-2030 (USD MILLION)
  • TABLE 284. THAILAND COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY HORSES, 2018-2030 (USD MILLION)
  • TABLE 285. THAILAND COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 286. THAILAND COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 287. THAILAND COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY MEDICATED FEED ADDITIVES, 2018-2030 (USD MILLION)
  • TABLE 288. THAILAND COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PHARMACEUTICAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 289. THAILAND COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 290. THAILAND COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 291. THAILAND COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2018-2030 (USD MILLION)
  • TABLE 292. THAILAND COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 293. THAILAND COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 294. VIETNAM COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 295. VIETNAM COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY CATS, 2018-2030 (USD MILLION)
  • TABLE 296. VIETNAM COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DOGS, 2018-2030 (USD MILLION)
  • TABLE 297. VIETNAM COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY HORSES, 2018-2030 (USD MILLION)
  • TABLE 298. VIETNAM COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 299. VIETNAM COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 300. VIETNAM COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY MEDICATED FEED ADDITIVES, 2018-2030 (USD MILLION)
  • TABLE 301. VIETNAM COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PHARMACEUTICAL DRUGS, 2